- Stocks
- Healthcare
- NASDAQ: CTMX

Price (delayed)

$5.58

Market cap

$362.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.23

Enterprise value

$52.99M

CTMX's equity has surged by 193% since the previous quarter and by 109% year-on-year

CTMX's quick ratio is up by 28% since the previous quarter and by 13% year-on-year

CytomX Therapeutics's net income has shrunk by 84% QoQ but it has increased by 20% YoY

The EPS has plunged by 73% from the previous quarter but it has grown by 27% YoY

The gross profit has declined by 34% since the previous quarter and by 14% year-on-year

CTMX's revenue is down by 34% since the previous quarter and by 14% year-on-year

What are the main financial stats of CTMX

Market
Valuations
Earnings

Shares outstanding

65.01M

Market cap

$362.76M

Enterprise value

$52.99M

Price to earnings (P/E)

N/A

Price to book (P/B)

2.48

Price to sales (P/S)

5.1

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

0.79

Revenue

$66.74M

EBIT

-$60.64M

EBITDA

-$54.39M

Free cash flow

$22.81M

Per share
Balance sheet
Liquidity

EPS

-$1.23

Free cash flow per share

$0.37

Book value per share

$2.25

Revenue per share

$1.09

TBVPS

$7.09

Total assets

$434.16M

Total liabilities

$288.14M

Debt

$20.81M

Equity

$146.02M

Working capital

$301.96M

Debt to equity

0.14

Current ratio

4.08

Quick ratio

4.03

Net debt/EBITDA

5.7

Margins
Efficiency
Dividend

EBITDA margin

-81.5%

Gross margin

100%

Net margin

-90.9%

Operating margin

-92.1%

Return on assets

-15.4%

Return on equity

-80.1%

Return on invested capital

-94.4%

Return on capital employed

-18%

Return on sales

-90.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the CytomX Therapeutics stock price performed over time

Intraday

-2.79%

1 week

-2.28%

1 month

-10.58%

1 year

-23.35%

YTD

-14.81%

QTD

-11.85%

How have CytomX Therapeutics's revenue and profit performed over time

Revenue

$66.74M

Gross profit

$66.74M

Operating income

-$61.44M

Net income

-$60.64M

Gross margin

100%

Net margin

-90.9%

CTMX's net margin has dropped by 177% since the previous quarter but it is up by 7% year-on-year

The company's operating margin has shrunk by 90% QoQ but it rose by 26% YoY

CytomX Therapeutics's net income has shrunk by 84% QoQ but it has increased by 20% YoY

The operating income is up by 37% year-on-year but it has declined by 26% since the previous quarter

What is CytomX Therapeutics's growth rate over time

What is CytomX Therapeutics stock price valuation

P/E

N/A

P/B

2.48

P/S

5.1

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

0.79

The EPS has plunged by 73% from the previous quarter but it has grown by 27% YoY

CTMX's equity has surged by 193% since the previous quarter and by 109% year-on-year

The stock's price to book (P/B) is 70% less than its 5-year quarterly average of 8.4 and 56% less than its last 4 quarters average of 5.6

The stock's P/S is 60% less than its 5-year quarterly average of 12.8 but 13% more than its last 4 quarters average of 4.5

CTMX's revenue is down by 34% since the previous quarter and by 14% year-on-year

How efficient is CytomX Therapeutics business performance

The ROIC has shrunk by 123% QoQ and by 70% YoY

The ROS has plunged by 95% from the previous quarter but it has grown by 22% YoY

CTMX's return on assets has dropped by 83% since the previous quarter but it is up by 21% year-on-year

CTMX's ROE is down by 38% since the previous quarter but it is up by 20% year-on-year

What is CTMX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CTMX.

How did CytomX Therapeutics financials performed over time

CTMX's total assets is 51% more than its total liabilities

CTMX's quick ratio is up by 28% since the previous quarter and by 13% year-on-year

The company's current ratio rose by 27% QoQ and by 8% YoY

CTMX's debt is 86% smaller than its equity

CTMX's equity has surged by 193% since the previous quarter and by 109% year-on-year

The debt to equity has dropped by 68% since the previous quarter and by 60% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.